Karyopharm Therapeutics’ (KPTI) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a report published on Monday,Benzinga reports. Royal Bank of Canada currently has a $3.00 price target on the stock.

Other equities research analysts also recently issued reports about the company. Piper Sandler lifted their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. Finally, StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Trading Down 2.1 %

Shares of KPTI opened at $0.59 on Monday. Karyopharm Therapeutics has a 12 month low of $0.58 and a 12 month high of $1.70. The business’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $0.77. The company has a market cap of $73.92 million, a price-to-earnings ratio of -0.51 and a beta of 0.06.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KPTI. Geode Capital Management LLC increased its holdings in Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after acquiring an additional 36,922 shares in the last quarter. FMR LLC increased its stake in shares of Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after purchasing an additional 76,510 shares in the last quarter. GSA Capital Partners LLP raised its position in shares of Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after purchasing an additional 792,283 shares during the period. Exchange Traded Concepts LLC raised its position in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after buying an additional 622,194 shares during the period. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).